Using advanced imaging techniques to diagnose liver cancer
Clinical Impact of 18F-FDGal PET/CT and PET/MRI in Patients Suspected of or Diagnosed With Hepatocellular Carcinoma
This study is testing if new imaging techniques can help doctors better detect and understand liver cancer in patients who might have it.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 125 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | University of Aarhus Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Aarhus) |
| Trial ID | NCT05871892 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of 18F-FDGal PET/CT and PET/MRI imaging techniques in patients suspected of or diagnosed with hepatocellular carcinoma (HCC). The study aims to determine if these advanced imaging modalities can improve the detection and characterization of HCC compared to traditional imaging methods. By focusing on newly-referred patients, the trial seeks to enhance diagnostic accuracy and potentially influence treatment decisions for this aggressive cancer. The study is conducted at Aarhus University Hospital in Denmark.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years who are newly-referred patients suspected of or diagnosed with hepatocellular carcinoma.
Not a fit: Patients who are pregnant, nursing, or have renal insufficiency may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic accuracy for hepatocellular carcinoma, allowing for earlier and more effective treatment options.
How similar studies have performed: While the use of PET imaging in cancer diagnosis is established, the specific application of 18F-FDGal PET/CT and PET/MRI for hepatocellular carcinoma is a novel approach that has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Newly-referred patients suspected of or diagnosed with HCC * Age above 18 years Exclusion Criteria: * The patient does not want to take part in the study * The responsible investigator determines that the patient is not qualified for a PET scan. * Patients who are offered systemic chemotherapy or best supportive care will be excluded. * Renal insufficiency (estimated glomerular filtration rate \[eGFR\] \<30 ml/min/1.73 m2 body surface area). * Pregnant or nursing patients.
Where this trial is running
Aarhus
- Aarhus University Hospital — Aarhus, Denmark (Recruiting)
Study contacts
- Study coordinator: Mona Kristiansen, MD
- Email: mkk@clin.au.dk
- Phone: +4527491598
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.